Receptor imaging in the thorax with PET

Area of Science:

• Nuclear medicine
• Molecular imaging
• Pharmacology

Background:

• The sympathetic and parasympathetic nervous systems regulate heart and lung function.
• Positron emission tomography (PET) is a powerful tool for in vivo molecular imaging.
• Understanding receptor distribution is crucial for diagnosing and treating cardiovascular and pulmonary diseases.

Purpose of the Study:

• To review the current status of PET imaging for sympathetic and parasympathetic receptors in the human heart and lung.
• To highlight the clinical applications and potential of developed PET radioligands.
• To discuss the progress and challenges in developing subtype-selective radioligands.

Main Methods:

• Review of existing literature on PET radioligands for adrenergic and muscarinic receptors.
• Analysis of studies evaluating radioligand performance in human subjects.
• Discussion of radioligand development for alpha-adrenoceptors, beta-adrenergic receptors, and muscarinic receptors.

Main Results:

• [11C]GB67 is a potential PET tracer for alpha-adrenoceptors, but requires further patient assessment.
• Potent PET radioligands like [11C]MQNB, [11C]CGP12177, and [11C]CGP12388 have been successfully evaluated in patients for beta-adrenergic and muscarinic systems.
• Quantitative receptor density measurements are feasible in the human heart, while qualitative assessments are possible in the lung.

Conclusions:

• PET imaging offers valuable insights into human heart and lung receptor pharmacology.
• Established radioligands enable quantitative and qualitative assessment of key receptor systems.
• Development of subtype-selective PET tracers remains an active area of research with future clinical potential.